Clinical Trial

COhort for Bardet-Bield Syndrome and Alström Syndrome for Translational Research Monocentric Interventional Study

Study acronym: COBBALT
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 10, 2021 (before its estimated February 2025 completion). Its status may not reflect the trial's current state.
Summary
ALMS and BBS syndromes are rare diseases with overlapping features of multiple sensory and metabolic impairments, including diabetes mellitus. There are to date no specific treatments available and limited information on the natural history of the diseases. the investigators aim to establish a French cohort for these diseases to improve patient care and assess the effect of actual therapies on quality of life. The purpose of this study is to establish a cohort of Bardet-Bield syndrome (BBS) and ALström syndrome (ALMS) patients in order to formalize and address questions concerning the in-depth natural clinical and biological history of the disease on the long term for a given patient, establish the impact on the quality of life of various clinical manifestations
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2020-07-02; most recent amendment 2021-09-09.
Trial Details
NCT Number NCT04461444
Lead Sponsor University Hospital, Strasbourg, France
Conditions Bardet-Biedl Syndrome, Alström Syndrome
Enrollment 350 participants
Start Date 2020-06-16
Primary Completion 2025-02 (estimated)
Study Completion 2035-02 (estimated)
Updated on ClinicalTrials.gov 2021-09-10